Solventum raises annual profit forecast on strong surgical product sales

reuters11-08

<a href="https://laohu8.com/S/SOLV">Solventum</a> raises annual profit forecast on strong surgical product sales

Nov 7 (Reuters) - 3M spin-off Solventum SOLV.N raised its annual profit forecast on Thursday, betting on strong sales of its wound care and surgical sterilization products.

The company now expects annual adjusted profit in the range of $6.50 to $6.65 per share, compared to its previous estimate of $6.30 to $6.50 per share.

Minnesota-based Solventum is one of the largest providers of sterilization devices, wound dressings, medical tape and other hospital consumables used by healthcare facilities.

The company's net income fell to $122 million, or 70 cents per share, in the quarter ended Sept. 30, from $460 million, or $2.66 per share, a year earlier.

The company's profit fell by more than 70% in August on higher expenses — its first results as an independent company.

CEO Bryan Hanson said in August that the company is "currently assessing primary markets and growth drivers, and our intent is to finalize these decisions before the end of the year."

Total third-quarter net sales was $2.08 billion, a 0.4% increase from a year earlier.

More than half of Solventum's revenue comes from its MedSurg business, which provides wound dressings and surgical equipment. Third-quarter sales in the segment came in at $1.18 billion.

On an adjusted basis, Solventum earned a profit of $1.64 per share during the third quarter.

(Reporting by Sneha S K in Bengaluru; Editing by Shailesh Kuber and Alan Barona)

((Sneha.SK@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481208157?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-08 05:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481208157","market":"us","top_or_hot":-1,"title":"Solventum raises annual profit forecast on strong surgical product sales","media":"reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/SOLV\">Solventum</a> raises annual profit forecast on strong surgical product sales</title></head><body><p>\n<span>Nov 7 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/MMM\">3M</a> spin-off Solventum <span>SOLV.N</span> raised its annual profit forecast on Thursday, betting on strong sales of its wound care and surgical sterilization products. </p><p>The company now expects annual adjusted profit in the range of $6.50 to $6.65 per share, compared to its previous estimate of $6.30 to $6.50 per share. </p><p>Minnesota-based Solventum is one of the largest providers of sterilization devices, wound dressings, medical tape and other hospital consumables used by healthcare facilities.</p><p>The company's net income fell to $122 million, or 70 cents per share, in the quarter ended Sept. 30, from $460 million, or $2.66 per share, a year earlier.</p><p>The company's profit <span>fell</span> by more than 70% in August on higher expenses — its first results as an independent company. </p><p>CEO Bryan Hanson said in August that the company is \"currently assessing primary markets and growth drivers, and our intent is to finalize these decisions before the end of the year.\"</p><p>Total third-quarter net sales was $2.08 billion, a 0.4% increase from a year earlier. </p><p>More than half of Solventum's revenue comes from its MedSurg business, which provides wound dressings and surgical equipment. Third-quarter sales in the segment came in at $1.18 billion.  </p><p>On an adjusted basis, Solventum earned a profit of $1.64 per share during the third quarter.</p><p> (Reporting by Sneha S K in Bengaluru; Editing by Shailesh Kuber and Alan Barona)</p><p> ((Sneha.SK@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Solventum raises annual profit forecast on strong surgical product sales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSolventum raises annual profit forecast on strong surgical product sales\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-08 05:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nL4N3ME2V1:1><strong>reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Solventum raises annual profit forecast on strong surgical product sales\nNov 7 (Reuters) - 3M spin-off Solventum SOLV.N raised its annual profit forecast on Thursday, betting on strong sales of its ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nL4N3ME2V1:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SOLV","symbol_name":"Solventum","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nL4N3ME2V1:1","article_id":"2481208157","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481208157","pubTimestamp":1731015264,"sourceInfo":null,"weMediaInfo":{"media_name":"reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Solventum raises annual profit forecast on strong surgical product sales Nov 7 (Reuters) - 3M spin-off Solventum SOLV.N raised its annual profit forecast on Thursday, betting on strong sales of its wo","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"SOLV":"Solventum"},"translate_title":"由于外科产品销售强劲，Solventum上调年度利润预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SOLV":0.9},"content_text":"Solventum raises annual profit forecast on strong surgical product sales\nNov 7 (Reuters) - 3M spin-off Solventum SOLV.N raised its annual profit forecast on Thursday, betting on strong sales of its wound care and surgical sterilization products. The company now expects annual adjusted profit in the range of $6.50 to $6.65 per share, compared to its previous estimate of $6.30 to $6.50 per share. Minnesota-based Solventum is one of the largest providers of sterilization devices, wound dressings, medical tape and other hospital consumables used by healthcare facilities.The company's net income fell to $122 million, or 70 cents per share, in the quarter ended Sept. 30, from $460 million, or $2.66 per share, a year earlier.The company's profit fell by more than 70% in August on higher expenses — its first results as an independent company. CEO Bryan Hanson said in August that the company is \"currently assessing primary markets and growth drivers, and our intent is to finalize these decisions before the end of the year.\"Total third-quarter net sales was $2.08 billion, a 0.4% increase from a year earlier. More than half of Solventum's revenue comes from its MedSurg business, which provides wound dressings and surgical equipment. Third-quarter sales in the segment came in at $1.18 billion.  On an adjusted basis, Solventum earned a profit of $1.64 per share during the third quarter. (Reporting by Sneha S K in Bengaluru; Editing by Shailesh Kuber and Alan Barona) ((Sneha.SK@thomsonreuters.com))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481208157"}